Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W
W
Wang
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E
JE
Cortes
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P
P
Lin
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J D
JD
Khoury
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D
D
Ai
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Tang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G
G
Tang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J L
JL
Jorgensen
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L J
LJ
Medeiros
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Hu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002898:Chromosomes, Human, Pair 8; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014314:Trisomy
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases